Alliancebernstein L.P. Has $574,000 Stake in Epizyme, Inc. (EPZM)

Alliancebernstein L.P. held its position in Epizyme, Inc. (NASDAQ:EPZM) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 38,000 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Alliancebernstein L.P. owned about 0.07% of Epizyme worth $574,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Principal Financial Group Inc. raised its stake in Epizyme by 1.5% in the 2nd quarter. Principal Financial Group Inc. now owns 95,572 shares of the biopharmaceutical company’s stock valued at $1,443,000 after acquiring an additional 1,399 shares during the period. Federated Investors Inc. PA raised its stake in Epizyme by 477.6% in the 2nd quarter. Federated Investors Inc. PA now owns 89,505 shares of the biopharmaceutical company’s stock valued at $1,352,000 after acquiring an additional 74,009 shares during the period. BB&T Securities LLC acquired a new position in Epizyme in the 2nd quarter valued at $181,000. Alps Advisors Inc. grew its holdings in Epizyme by 5.5% in the 2nd quarter. Alps Advisors Inc. now owns 52,675 shares of the biopharmaceutical company’s stock valued at $795,000 after buying an additional 2,769 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in Epizyme by 83.3% in the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 6,072 shares in the last quarter. Institutional investors and hedge funds own 72.20% of the company’s stock.

Shares of Epizyme, Inc. (NASDAQ EPZM) opened at $14.20 on Friday.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. analysts forecast that Epizyme, Inc. will post -2.34 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/11/04/alliancebernstein-l-p-has-574000-stake-in-epizyme-inc-epzm.html.

In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $16.81, for a total transaction of $252,150.00. Following the transaction, the insider now directly owns 23,123 shares of the company’s stock, valued at $388,697.63. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David M. Mott purchased 200,000 shares of Epizyme stock in a transaction dated Monday, September 18th. The shares were acquired at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the transaction, the director now owns 6,000 shares of the company’s stock, valued at approximately $91,500. The disclosure for this purchase can be found here. Insiders sold 45,000 shares of company stock valued at $733,950 in the last three months. 25.20% of the stock is currently owned by insiders.

A number of research analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Epizyme in a report on Thursday. Leerink Swann reaffirmed an “outperform” rating and issued a $22.00 price objective (down from $28.00) on shares of Epizyme in a report on Thursday. Royal Bank Of Canada lowered Epizyme from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $20.00 to $16.00 in a report on Thursday. Cann reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Epizyme in a report on Thursday. Finally, Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Monday, October 16th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $22.67.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme, Inc. (NASDAQ:EPZM).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

What are top analysts saying about Epizyme Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Epizyme Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit